Novel Biologics: Designed by evolution.
Discovered by AI.
AI-derived novel biologics
AMPLY Discovery uses machine learning and synthetic biology to mine vast biological data to discover novel drug and nutraceutical candidates. Using a proprietary in silico and in vitro hybrid platform to discover best-in-class molecules AMPLY is helping tackle some of humankind’s greatest challenges such as cancer, MDR infections and metabolic diseases.
biomining biological big data for novel biologics
Reinventing Traditional Drug Discovery
AMPLY Discovery is powered by Darwin. Uniquely, rather than using AI to develop new drugs from scratch using solely rational design principles, AMPLY adopts a deep-mining approach, scanning regions of genetic code no other tool can, exploring the “dark matter” of genomic datasets to find natural antimicrobials shaped by thousands of years of evolution – many from unculturable or unknown organisms. Evolution and competitive pressure in ecosystems leads to a microbial arms race between different classes of life. Hidden in metagenomic and genomic data is the key to the antimicrobial weapons of potentially millions of unculturable or unknown organisms. Life finds a way, then AMPLY exploits it.
years of development
The amplyfolio ai platform
Bringing financial style stock selection to drug discovery
The digital biome offers huge potential for recovering proteinaceous compounds shaped by tens of thousands of years of evolution. But finding good compounds that can be synthesised artificially and work in the lab is a challenge. AMPLYfolio AI, our award-winning software platform, meets this challenge through combining bioinformatic techniques and approaches from other industries (such as asset management and predictive marketing) alongside a unique human decision-making dashboard which focuses on novelty and IP protectability.
year research commenced
novel molecules bioprinted
molecules characterised in detail
novel class leading molecules identified